12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder

Dan J. Stein, Jon Paul Khoo, Antti Ahokas, Marek Jarema, Michael Van Ameringen, Livia Vavrusova, Cyril Hӧschl, Michael Bauer, Istvan Bitter, Sergey N. Mosolov, Valérie Olivier, Sophie Matharan, Françoise Picarel-Blanchot, Christian de Bodinat

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of '12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder'. Together they form a unique fingerprint.

Medicine & Life Sciences